PDCD1 and hepatocellular carcinoma: In contrast, HBV-positive patients who received a combination of anti-PD-1/PD-L1 plus anti-VEGF therapy achieved similar ORRs and DCRs to those of HBV-negative patients (18), a combination therapy maybe more suitable for Chinese HCC patients.